Selected research
Industry Research
Immune Mediated Tumor Killing Assays Service Industry Research Report 2026
Market perspective
The global Immune Mediated Tumor Killing Assays Service market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Immune Mediated Tumor Killing Assays Service market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Immune Mediated Tumor Killing Assays Service market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Immune Mediated Tumor Killing Assays Service market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Immune Mediated Tumor Killing Assays Service include Agilent, Laboratories, Explicyte, Reaction Biology, Axion BioSystems, Sartorius, ICE Bioscience, Shanghai Saily Biotechnology and ProBio, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Immune Mediated Tumor Killing Assays Service market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Immune Mediated Tumor Killing Assays Service.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Immune Mediated Tumor Killing Assays Service Market by Company
Agilent
Laboratories
Explicyte
Reaction Biology
Axion BioSystems
Sartorius
ICE Bioscience
Shanghai Saily Biotechnology
ProBio
Charles River
Imodels
Xeno Diagnostics
Cyagen
MarinBio
Pharmalegacy
Celentyx
Crown Bioscience
Cellomatics Biosciences
Immune Mediated Tumor Killing Assays Service Segment by Type
Cytotoxic T Cell Assay
Natural Killer (NK) Cell Assay
Other
Immune Mediated Tumor Killing Assays Service Segment by Application
Cancer Research
Infectious Disease Research
Immunotherapy Development
Immune Mediated Tumor Killing Assays Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immune Mediated Tumor Killing Assays Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Immune Mediated Tumor Killing Assays Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immune Mediated Tumor Killing Assays Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Immune Mediated Tumor Killing Assays Service companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cytotoxic T Cell Assay
- Natural Killer (NK) Cell Assay
- Other
Applications
- Cancer Research
- Infectious Disease Research
- Immunotherapy Development
Companies covered
- Agilent
- Laboratories
- Explicyte
- Reaction Biology
- Axion BioSystems
- Sartorius
- ICE Bioscience
- Shanghai Saily Biotechnology
- ProBio
- Charles River
- Imodels
- Xeno Diagnostics
- Cyagen
- MarinBio
- Pharmalegacy
- Celentyx
- Crown Bioscience
- Cellomatics Biosciences
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Immune Mediated Tumor Killing Assays Service by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Cytotoxic T Cell Assay
- 2.2.3 Natural Killer (NK) Cell Assay
- 2.2.4 Other
- 2.3 Immune Mediated Tumor Killing Assays Service by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Cancer Research
- 2.3.3 Infectious Disease Research
- 2.3.4 Immunotherapy Development
- 2.4 Assumptions and Limitations
3 Immune Mediated Tumor Killing Assays Service Breakdown Data by Type
- 3.1 Global Immune Mediated Tumor Killing Assays Service Historic Market Size by Type (2021-2026)
- 3.2 Global Immune Mediated Tumor Killing Assays Service Forecasted Market Size by Type (2027-2032)
4 Immune Mediated Tumor Killing Assays Service Breakdown Data by Application
- 4.1 Global Immune Mediated Tumor Killing Assays Service Historic Market Size by Application (2021-2026)
- 4.2 Global Immune Mediated Tumor Killing Assays Service Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Immune Mediated Tumor Killing Assays Service Market Perspective (2021-2032)
- 5.2 Global Immune Mediated Tumor Killing Assays Service Growth Trends by Region
- 5.2.1 Global Immune Mediated Tumor Killing Assays Service Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Immune Mediated Tumor Killing Assays Service Historic Market Size by Region (2021-2026)
- 5.2.3 Immune Mediated Tumor Killing Assays Service Forecasted Market Size by Region (2027-2032)
- 5.3 Immune Mediated Tumor Killing Assays Service Market Dynamics
- 5.3.1 Immune Mediated Tumor Killing Assays Service Industry Trends
- 5.3.2 Immune Mediated Tumor Killing Assays Service Market Drivers
- 5.3.3 Immune Mediated Tumor Killing Assays Service Market Challenges
- 5.3.4 Immune Mediated Tumor Killing Assays Service Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Immune Mediated Tumor Killing Assays Service Players by Revenue
- 6.1.1 Global Top Immune Mediated Tumor Killing Assays Service Players by Revenue (2021-2026)
- 6.1.2 Global Immune Mediated Tumor Killing Assays Service Revenue Market Share by Players (2021-2026)
- 6.2 Global Immune Mediated Tumor Killing Assays Service Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Immune Mediated Tumor Killing Assays Service Head Office and Area Served
- 6.4 Global Immune Mediated Tumor Killing Assays Service Players, Product Type & Application
- 6.5 Global Immune Mediated Tumor Killing Assays Service Manufacturers Established Date
- 6.6 Global Immune Mediated Tumor Killing Assays Service Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Immune Mediated Tumor Killing Assays Service Market Size (2021-2032)
- 7.2 North America Immune Mediated Tumor Killing Assays Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Immune Mediated Tumor Killing Assays Service Market Size by Country (2021-2026)
- 7.4 North America Immune Mediated Tumor Killing Assays Service Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Immune Mediated Tumor Killing Assays Service Market Size (2021-2032)
- 8.2 Europe Immune Mediated Tumor Killing Assays Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Immune Mediated Tumor Killing Assays Service Market Size by Country (2021-2026)
- 8.4 Europe Immune Mediated Tumor Killing Assays Service Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Immune Mediated Tumor Killing Assays Service Market Size (2021-2032)
- 9.2 Asia-Pacific Immune Mediated Tumor Killing Assays Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Immune Mediated Tumor Killing Assays Service Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Immune Mediated Tumor Killing Assays Service Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Immune Mediated Tumor Killing Assays Service Market Size (2021-2032)
- 10.2 South America Immune Mediated Tumor Killing Assays Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Immune Mediated Tumor Killing Assays Service Market Size by Country (2021-2026)
- 10.4 South America Immune Mediated Tumor Killing Assays Service Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Immune Mediated Tumor Killing Assays Service Market Size (2021-2032)
- 11.2 Middle East & Africa Immune Mediated Tumor Killing Assays Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Immune Mediated Tumor Killing Assays Service Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Immune Mediated Tumor Killing Assays Service Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Agilent
- 12.1.1 Agilent Company Information
- 12.1.2 Agilent Business Overview
- 12.1.3 Agilent Revenue in Immune Mediated Tumor Killing Assays Service Business (2021-2026)
- 12.1.4 Agilent Immune Mediated Tumor Killing Assays Service Product Portfolio
- 12.1.5 Agilent Recent Developments
- 12.2 Laboratories
- 12.2.1 Laboratories Company Information
- 12.2.2 Laboratories Business Overview
- 12.2.3 Laboratories Revenue in Immune Mediated Tumor Killing Assays Service Business (2021-2026)
- 12.2.4 Laboratories Immune Mediated Tumor Killing Assays Service Product Portfolio
- 12.2.5 Laboratories Recent Developments
- 12.3 Explicyte
- 12.3.1 Explicyte Company Information
- 12.3.2 Explicyte Business Overview
- 12.3.3 Explicyte Revenue in Immune Mediated Tumor Killing Assays Service Business (2021-2026)
- 12.3.4 Explicyte Immune Mediated Tumor Killing Assays Service Product Portfolio
- 12.3.5 Explicyte Recent Developments
- 12.4 Reaction Biology
- 12.4.1 Reaction Biology Company Information
- 12.4.2 Reaction Biology Business Overview
- 12.4.3 Reaction Biology Revenue in Immune Mediated Tumor Killing Assays Service Business (2021-2026)
- 12.4.4 Reaction Biology Immune Mediated Tumor Killing Assays Service Product Portfolio
- 12.4.5 Reaction Biology Recent Developments
- 12.5 Axion BioSystems
- 12.5.1 Axion BioSystems Company Information
- 12.5.2 Axion BioSystems Business Overview
- 12.5.3 Axion BioSystems Revenue in Immune Mediated Tumor Killing Assays Service Business (2021-2026)
- 12.5.4 Axion BioSystems Immune Mediated Tumor Killing Assays Service Product Portfolio
- 12.5.5 Axion BioSystems Recent Developments
- 12.6 Sartorius
- 12.6.1 Sartorius Company Information
- 12.6.2 Sartorius Business Overview
- 12.6.3 Sartorius Revenue in Immune Mediated Tumor Killing Assays Service Business (2021-2026)
- 12.6.4 Sartorius Immune Mediated Tumor Killing Assays Service Product Portfolio
- 12.6.5 Sartorius Recent Developments
- 12.7 ICE Bioscience
- 12.7.1 ICE Bioscience Company Information
- 12.7.2 ICE Bioscience Business Overview
- 12.7.3 ICE Bioscience Revenue in Immune Mediated Tumor Killing Assays Service Business (2021-2026)
- 12.7.4 ICE Bioscience Immune Mediated Tumor Killing Assays Service Product Portfolio
- 12.7.5 ICE Bioscience Recent Developments
- 12.8 Shanghai Saily Biotechnology
- 12.8.1 Shanghai Saily Biotechnology Company Information
- 12.8.2 Shanghai Saily Biotechnology Business Overview
- 12.8.3 Shanghai Saily Biotechnology Revenue in Immune Mediated Tumor Killing Assays Service Business (2021-2026)
- 12.8.4 Shanghai Saily Biotechnology Immune Mediated Tumor Killing Assays Service Product Portfolio
- 12.8.5 Shanghai Saily Biotechnology Recent Developments
- 12.9 ProBio
- 12.9.1 ProBio Company Information
- 12.9.2 ProBio Business Overview
- 12.9.3 ProBio Revenue in Immune Mediated Tumor Killing Assays Service Business (2021-2026)
- 12.9.4 ProBio Immune Mediated Tumor Killing Assays Service Product Portfolio
- 12.9.5 ProBio Recent Developments
- 12.10 Charles River
- 12.10.1 Charles River Company Information
- 12.10.2 Charles River Business Overview
- 12.10.3 Charles River Revenue in Immune Mediated Tumor Killing Assays Service Business (2021-2026)
- 12.10.4 Charles River Immune Mediated Tumor Killing Assays Service Product Portfolio
- 12.10.5 Charles River Recent Developments
- 12.11 Imodels
- 12.11.1 Imodels Company Information
- 12.11.2 Imodels Business Overview
- 12.11.3 Imodels Revenue in Immune Mediated Tumor Killing Assays Service Business (2021-2026)
- 12.11.4 Imodels Immune Mediated Tumor Killing Assays Service Product Portfolio
- 12.11.5 Imodels Recent Developments
- 12.12 Xeno Diagnostics
- 12.12.1 Xeno Diagnostics Company Information
- 12.12.2 Xeno Diagnostics Business Overview
- 12.12.3 Xeno Diagnostics Revenue in Immune Mediated Tumor Killing Assays Service Business (2021-2026)
- 12.12.4 Xeno Diagnostics Immune Mediated Tumor Killing Assays Service Product Portfolio
- 12.12.5 Xeno Diagnostics Recent Developments
- 12.13 Cyagen
- 12.13.1 Cyagen Company Information
- 12.13.2 Cyagen Business Overview
- 12.13.3 Cyagen Revenue in Immune Mediated Tumor Killing Assays Service Business (2021-2026)
- 12.13.4 Cyagen Immune Mediated Tumor Killing Assays Service Product Portfolio
- 12.13.5 Cyagen Recent Developments
- 12.14 MarinBio
- 12.14.1 MarinBio Company Information
- 12.14.2 MarinBio Business Overview
- 12.14.3 MarinBio Revenue in Immune Mediated Tumor Killing Assays Service Business (2021-2026)
- 12.14.4 MarinBio Immune Mediated Tumor Killing Assays Service Product Portfolio
- 12.14.5 MarinBio Recent Developments
- 12.15 Pharmalegacy
- 12.15.1 Pharmalegacy Company Information
- 12.15.2 Pharmalegacy Business Overview
- 12.15.3 Pharmalegacy Revenue in Immune Mediated Tumor Killing Assays Service Business (2021-2026)
- 12.15.4 Pharmalegacy Immune Mediated Tumor Killing Assays Service Product Portfolio
- 12.15.5 Pharmalegacy Recent Developments
- 12.16 Celentyx
- 12.16.1 Celentyx Company Information
- 12.16.2 Celentyx Business Overview
- 12.16.3 Celentyx Revenue in Immune Mediated Tumor Killing Assays Service Business (2021-2026)
- 12.16.4 Celentyx Immune Mediated Tumor Killing Assays Service Product Portfolio
- 12.16.5 Celentyx Recent Developments
- 12.17 Crown Bioscience
- 12.17.1 Crown Bioscience Company Information
- 12.17.2 Crown Bioscience Business Overview
- 12.17.3 Crown Bioscience Revenue in Immune Mediated Tumor Killing Assays Service Business (2021-2026)
- 12.17.4 Crown Bioscience Immune Mediated Tumor Killing Assays Service Product Portfolio
- 12.17.5 Crown Bioscience Recent Developments
- 12.18 Cellomatics Biosciences
- 12.18.1 Cellomatics Biosciences Company Information
- 12.18.2 Cellomatics Biosciences Business Overview
- 12.18.3 Cellomatics Biosciences Revenue in Immune Mediated Tumor Killing Assays Service Business (2021-2026)
- 12.18.4 Cellomatics Biosciences Immune Mediated Tumor Killing Assays Service Product Portfolio
- 12.18.5 Cellomatics Biosciences Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst